Peptide Impurities

Peptide impurities are unwanted chemical substances present in a peptide drug substance or product. They originate from incomplete coupling during solid-phase synthesis (deletion sequences, truncated fragments), amino acid racemization (diastereomers), chemical degradation during storage (deamidation, oxidation, beta-elimination), or residual synthesis reagents (trifluoroacetic acid salts, scavengers, organic solvents).

Regulatory authorities enforce strict thresholds on peptide impurities under ICH Q3A/B guidelines. Impurities exceeding 0.1% must be identified, as they can cause toxic side effects or trigger dangerous anti-drug antibody responses in humans.

Purity is not a cosmetic detail. A peptide sold as “98% pure” can still contain a few percent of other substances, and those substances are not inert filler. Deletion sequences, oxidised fragments, diastereomers and leftover counter-ions such as trifluoroacetate are chemically different molecules with their own possible effects. A 2014 review of peptide medicines catalogued these impurity types and noted that they can even distort early laboratory studies, leading researchers to wrong conclusions about what a peptide does.

Approved peptide drugs are made under Good Manufacturing Practice, with impurity limits set and checked by regulators. Products sold online as research chemicals sit outside that system. The FDA has warned about unapproved semaglutide and tirzepatide products falsely labelled “for research purposes” or “not for human consumption”, describing them as being of unknown quality, and has said that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the one in approved drugs.

Impurities also matter to the immune system. A structurally altered peptide may, in principle, be recognised as foreign and prompt anti-drug antibodies. This is why the FDA’s abbreviated pathway for generic synthetic peptides asks manufacturers to identify impurities that differ from the reference product and to assess their immunogenicity risk. A single purity number on a certificate cannot answer that question on its own.

“A high purity percentage means the product is safe”

Purity, usually measured by HPLC, reports how much of the detected material is the target peptide. It does not say what the remaining fraction is, whether endotoxin or solvent residues are present, or whether the vial holds the stated amount. It also says nothing about the safety of the peptide itself, which for many unapproved compounds has never been established in humans.

“Impurities only come from careless manufacturing”

Some impurities are built into the chemistry. Solid-phase synthesis can leave deletion or insertion sequences, deprotection steps can cause racemisation, and peptides keep degrading after manufacture through oxidation, β-elimination and related reactions. Good manufacturing practice controls these impurities; it does not eliminate them. Poor storage and handling after a product leaves the factory can add further degradation products.

“Compounded or copycat versions are chemically identical to the brand”

Not necessarily. Regulators ask generic peptide makers to show that their impurities are comparable to the reference product, precisely because differences can matter. The FDA has also stated that the semaglutide salt forms used by some compounders are different active ingredients from the one in approved products, and that it has no information on whether they share the same chemical and pharmacological properties.

What are the most common peptide impurities?

The main groups are synthesis-related impurities (deletion and insertion sequences, diastereomers from racemisation, incompletely deprotected side chains and residual counter-ions such as trifluoroacetate) and degradation products formed through oxidation, β-elimination, pyroglutamate or succinimide formation. Finished products can also contain breakdown products formed between the peptide and excipients. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis describes these groups in detail.

Can peptide impurities cause an immune reaction?

They can, at least in principle. A modified or aggregated peptide may be recognised by the immune system differently from the intended sequence, which could lead to anti-drug antibodies. For this reason the FDA’s generic peptide pathway asks for an immunogenicity risk assessment of new or increased impurities. How often this causes clinical problems varies by product, and for unregulated peptides it is largely unknown.

How are peptide impurities detected?

The standard tools are high-performance liquid chromatography (HPLC), which separates the components of a sample, and mass spectrometry, which identifies them by mass. Used together they can reveal deletion sequences, oxidation products and other related substances. Each method has blind spots, so a single test, or a certificate that reports only one HPLC percentage, gives an incomplete picture.

Are research peptides tested for impurities?

Some sellers supply certificates of analysis, but these are not reviewed by any regulator and their quality and independence vary. The FDA describes unapproved GLP-1 products sold “for research purposes” as being of unknown quality and urges consumers not to buy them. A product sold outside the regulated supply chain has no enforced impurity limits.